Familial pancreatic cancer

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 4, 2008, Pages 387-397

  Jørgensen, Maiken Thyregod ^a   Mortensen, Michael Bau ^a   Gerdes, Anne Marie ^a   De Muckadell, Ove B Schaffalitzky ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ASPIRATION BIOPSY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DYSPLASIA; ENDOSCOPIC ECHOGRAPHY; FAMILIAL CANCER; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GENETIC PREDISPOSITION; HEALTH CARE COST; HEALTH PROGRAM; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 41349104493     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701775229     Document Type: Review

References (88)

1. Lynch HT, Brand RE, Deters CA, Shaw TG, Lynch JF. Hereditary pancreatic cancer. Pancreatology 2001;1:466-71.
2. Evans JP, Evans JP, Burke W, Chen R, Bennett RL, Schmidt RA, et al. Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. J Med Genet 1995;32:330-5.
3. Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr, Smyrk T, Fitzsimmons ML, McClellan J. Familial pancreatic cancer (Part 1): genetic pathology review. Nebr Med J 1989;74:109-12.
4. Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, Goggins M, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-44.
5. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64:2634-8.
6. Lynch HT, Fitzsimmons ML, Smyrk TC, Lanspa SJ, Watson P, McClellan J, et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990;85:54-60.
7. Fernandez E, La Vecchia C, Decarli A. Attributable risks for pancreatic cancer in northern Italy. Cancer Epidemiol Biomarkers Prev 1996;5:23-7.
8. Ojajärvi IA, Partanen TJ, Ahlbom A, Boffetta P, Hakulinen T, Jourenkova N, et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 2000;57:316-24.
9. Neglia JP, FitzSimmons SC, Maisonneuve P, Schöni MH, Schöni-Affolter F, Corey M, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995;332:494-9.
10. Fernandez E, La Vecchia C, Porta M, Negri E, d'Avanzo B, Boyle P. Pancreatitis and the risk of pancreatic cancer. Pancreas 1995;11:185-9.
11. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442-6.
12. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809-11.
13. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-53.
14. Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23:251-75.
15. Wong T, Howes N, Threadgold J, Smart HL, Lombard MG, Gilmore I, et al. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology 2001;1:486-509.
16. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
17. Langer P, Rothmund M, Bartsch DK. Prophylactic pancreas surgery. Chirurgie 2006;77:25-32.
18. Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2003;103:525-30.
19. Bartsch DK, Kress R, Sina-Frey M, Grützmann R, Gerdes B, Pilarsky C, et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer 2004;110:902-6.
20. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
21. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003;124:1292-9.
22. Senior K. Late-onset diabetes and the link with pancreatic cancer. Lancet Oncol 2005;6:641.
23. Huxley R, Owen CG, Whincup PH, Cook DG, Colman S, Collins R. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-83.
24. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004;59:99-111.
25. Tarpila E, Borch K, Kullman E, Liedberg G. Pancreatic cancer. Ann Chir Gynaecol 1986;75:146-50.
26. Grahm AL, Andren-Sandberg A. Prospective evaluation of pain in exocrine pancreatic cancer. Digestion 1997;58:542-9.
27. DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol 1999;10 Suppl 4:140-2.
28. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001;1:477-85.
29. Bartsch DK, Sina-Frey M, Ziegler A, Hahn SA, Przypadlo E, Kress R, et al. Update of familial pancreatic cancer in Germany. Pancreatology 2001;1:510-6.
30. Neoptolemos JP, Lemoine NR, Ching CH, Rhodes JM. Cancer of the pancreas and ampulla of Vater. In: Fielding JWL, Allum WH, editors. Premalignancy and Early Cancer in General Surgery. Oxford: Oxford Press, 1996; pp 66-100.
31. Bramhall S, Neoptolemos JP. Epidemiology of pancreatic cancer. In: Beger HG, Carr-Locke DL, Russell RCG, Büchler M, Neoptolemos JP, Saar M, editors. The pancreas. Boston: Blackwell Scientific; 1998. pp 889-906.
32. Finch MD, Howes N, Ellis I, Mountford R, Sutton R, Raraty M, et al. Hereditary pancreatitis and familial pancreatic cancer. Digestion 1997;58:564-9.
33. Silverman DT, Dunn JA, Hoover RN, Schiffman M, Lillemoe KD, Schoenberg JB, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994;86:1510-6.
34. Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Ginès MA, et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 2004;99:492-501.
35. Müller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging. Radiology 1994;190:745-51.
36. Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA, Charnsangavej C. Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. Abdom Imaging 2007;32:660-7.
37. Pamuklar E, Semelka RC. MR imaging of the pancreas. Magnetic Res Imaging Clin N Am 2005;13:313-30.
38. Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:227-51.
39. Klapman JB, Chang KJ, Lee JG, Nguyen P. Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer. Am J Gastroenterol 2005;100:2658-61.
40. Berberat P, Friess H, Kashiwagi M, Beger HG, Büchler MW. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999;23:882-7.
41. Friess H, Langhans J, Ebert M, Beger HG, Stollfuss J, Reske SN, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995;36:771-7.
42. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995;195:339-44.
43. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am 2000;84:707-18.
44. Mortensen MB, Fristrup C, Holm FS, Pless T, Durup J, Ainsworth AP, et al. Prospective evaluation of patient tolerability, satisfaction with patient information, and complications in endoscopic ultrasonography. Endoscopy 2005;37:146-53.
45. Voss M, Hammel P, Molas G, Palazzo L, Dancour A, O'Toole D, et al. Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut 2000;46:244-9.
46. Raut CP, Grau AM, Staerkel GA, Kaw M, Tamm EP, Wolff RA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 2003;7:118-26.
47. Gress F, Gottlieb K, Sherman S, Lehman G. Endoscopic ultrasonography- guided fine-needle aspiration biopsy of suspected pancreatic cancer. Ann Intern Med 2001;134:459-64.
48. Micames C, Jowell PS, White R, Paulson E, Nelson R, Morse M, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 2003;58:690-5.
49. Harewood GC, Wiersema LM, Halling AC, Keeney GL, Salamao DR, Wiersema MJ. Influence of EUS training and pathology interpretation on accuracy of EUS-guided fine needle aspiration of pancreatic masses. Gastrointest Endosc 2002;55:669-73.
50. Williams DB, Sahai AV, Aabakken L, Penman ID, van Velse A, Webb J, et al. Endoscopic ultrasound guided fine needle aspiration biopsy: a large single centre experience. Gut 1999;44:720-6.
51. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997;45:387-93.
52. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-55.
53. Topazian M, Enders F, Kimmey M, Brand R, Chak A, Clain J, et al. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc 2007;66:62-7.
54. Mertz H, Gautam S. The learning curve for EUS-guided FNA of pancreatic cancer. Gastrointest Endosc 2004;59:33-7.
55. Kekis PB, Friess H, Kleeff J, Büchler MW. Timing and extent of surgical intervention in patients from hereditary pancreatic cancer kindreds. Pancreatology 2001;15:525-30.
56. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57:2140-3.
57. Löhr M, Maisonneuve P, Lowenfels AB. K-Ras mutations and benign pancreatic disease. Int J Pancreatol 2000;27:93-103.
58. Ritts RE, Pitt HA. CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am 1998;7:93-101.
59. Malesci A, Tommasini MA, Bonato C, Bocchia P, Bersani M, Zerbi A, et al. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987;92:60-7.
60. Pasquali C, Sperti C, D'Andrea AA, Bonadimani B, Del Favero G, Petrin P, et al. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer. Pancreas 1987;2:34-7.
61. Benini L, Cavallini G, Zordan D, Rizzotti P, Rigo L, Brocco G, et al. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988;3:61-6.
62. Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988;61:2100-8.
63. Alexander JC, Silverman NA, Chretien PB. Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA 1976;235:1975-9.
64. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986;90:343-9.
65. Kuno N, Kurimoto K, Fukushima M, Hayakawa T, Shibata T, Suzuki T, et al. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a prospective study in multi-institutions. Pancreas 1994;9:725-30.
66. Maitra A, Fukushima N, Takaori K, Hruban RH. Precursors to invasive pancreatic cancer. Adv Anat Pathol 2005;12:81-91.
67. Canto MI. Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin Oncol 2007;34:295-302.
68. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22:163-9.
69. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976;36:2690-8.
70. Brune K, Abe T, Canto M, O'Malley L, Klein AP, Maitra A, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006;30:1067-76.
71. Schwartz AM, Henson DE. Familial and sporadic pancreatic carcinoma, epidemiologic concordance. Am J Surg Pathol 2007;31:645-6.
72. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
73. Pelaez-Luna M, Chari ST, Smyrk TC, Takahashi N, Clain JE, Levy MJ, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 2007;102:1759-64.
74. Salvia R, Crippa S, Falconi M, Bassi C, Guarise A, Scarpa A, et al. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut 2007;56:1086-90.
75. Schmidt CM, Lillemoe KD. IPMN-controversies in an "epidemic". J Surg Oncol 2006;94:91-3.
76. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28:977-87.
77. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003;16:996-1006.
78. Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 2005;6:437-45.
79. Billings BJ, Christein JD, Harmsen WS, Harrington JR, Chari ST, Que FG, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg 2005;9:1059-66.
80. Dresler CM, Fortner JG, McDermott K, Bajorunas DR. Metabolic consequences of (regional) total pancreatectomy. Ann Surg 1991;214:131-40.
81. Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol 2004;18:947-55.
82. Rieder H, Bartsch DK. Familial pancreatic cancer. Fam Cancer 2004;3:69-74.
83. Charpentier KP, Brentnall TA, Bronner MP, Byrd D, Marsh C. A new indication for pancreas transplantation: high grade pancreatic dysplasia. Clin Transplant 2004;18:105-7.
84. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003;57:23-9.
85. van der Maas PJ, de Koning HJ, van Ineveld BM, van Oortmarssen GJ, Habbema JD, Lubbe KT, et al. The cost-effectiveness of breast cancer screening. Int J Cancer 1989;43:1055-60.
86. Provenzale D. Cost-effectiveness of screening the average-risk population for colorectal cancer. Gastrointest Endosc Clin N Am 2002;12:93-109.
87. Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary nonpolyposis colorectal cancer. Int J Technol Assess Health Care 2007;23:89-95.
88. Latchford A, Greenhalf W, Vitone LJ, Neoptolemos JP, Lancaster GA, Phillips RK. Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg 2006;93:1446-55.